CC
ABBV icon

ClearArc Capital’s AbbVie ABBV Stock Holding History

ClearArc Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$1.22M Sell
13,796
-6,402
-32% -$531K 0.48% 49
2019
Q3 		$1.53M Buy
20,198
+97
+0.5% +$6.65K 0.44% 54
2019
Q2 		$1.46M Sell
20,101
-2,588
-11% -$203K 0.43% 54
2019
Q1 		$1.83M Sell
22,689
-1,167
-5% -$95.5K 0.49% 47
2018
Q4 		$2.2M Sell
23,856
-21,381
-47% -$1.88M 0.66% 32
2018
Q3 		$4.28M Sell
45,237
-2,120
-4% -$201K 0.56% 45
2018
Q2 		$4.39M Sell
47,357
-2,542
-5% -$248K 0.62% 38
2018
Q1 		$4.72M Sell
49,899
-30,855
-38% -$3.39M 0.71% 32
2017
Q4 		$7.81M Buy
80,754
+7,774
+11% +$733K 1.06% 19
2017
Q3 		$6.49M Sell
72,980
-5,195
-7% -$395K 0.97% 22
2017
Q2 		$5.67M Buy
78,175
+174
+0.2% +$11.7K 0.92% 25
2017
Q1 		$5.08M Buy
78,001
+5,759
+8% +$362K 0.85% 28
2016
Q4 		$4.52M Buy
72,242
+1,068
+2% +$65.2K 0.81% 30
2016
Q3 		$4.49M Buy
71,174
+1,471
+2% +$95.2K 0.85% 29
2016
Q2 		$4.32M Buy
69,703
+27,427
+65% +$1.67M 0.84% 28
2016
Q1 		$2.42M Buy
42,276
+542
+1% +$30.2K 0.51% 48
2015
Q4 		$2.47M Sell
41,734
-1,212
-3% -$69.8K 0.52% 46
2015
Q3 		$2.34M Sell
42,946
-13,013
-23% -$847K 0.49% 50
2015
Q2 		$3.76M Buy
55,959
+9,306
+20% +$608K 0.69% 29
2015
Q1 		$2.73M Buy
46,653
+4,229
+10% +$255K 0.56% 42
2014
Q4 		$2.78M Buy
42,424
+3,080
+8% +$194K 0.57% 38
2014
Q3 		$2.27M Buy
39,344
+1,039
+3% +$57.7K 0.51% 46
2014
Q2 		$2.16M Buy
38,305
+4,224
+12% +$222K 0.5% 52
2014
Q1 		$1.75M Buy
34,081
+1,829
+6% +$92.4K 0.43% 63
2013
Q4 		$1.7M Buy
32,252
+586
+2% +$28.8K 0.44% 61
2013
Q3 		$1.42M Buy
31,666
+1,241
+4% +$55K 0.4% 69
2013
Q2 		$1.26M Buy
+30,425
New +$1.33M 0.34% 86

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

ClearArc Capital's ABBV Position: Q4 2019 in Review

ClearArc Capital reduced its AbbVie (ABBV) stake by 32% in Q4 2019, selling an estimated $531K and leaving 13,796 shares worth $1.22M. The position accounts for 0.48% of the portfolio, ranked #49.

ClearArc Capital first reported a position in ABBV in Q2 2013 and has held it in 27 quarters since. The position peaked at $7.81M in Q4 2017. 2,244 funds tracked by Wall St. Rank hold ABBV as of Q4 2019.

  • ClearArc Capital held 13,796 shares of AbbVie worth $1.22M as of Q4 2019.
  • ClearArc Capital sold 6,402 AbbVie shares in Q4 2019, an estimated $531K.
  • AbbVie made up 0.48% of ClearArc Capital's portfolio in Q4 2019, its #49 holding.
  • ClearArc Capital first reported a position in AbbVie in Q2 2013 and has held it in 27 quarters since.
  • ClearArc Capital's AbbVie position peaked at $7.81M in Q4 2017.
  • 2,244 funds tracked by Wall St. Rank held AbbVie as of Q4 2019.

Based on ClearArc Capital's 13F filing for Q4 2019, filed 14 Feb 2020.